GSTM1 and chronic kidney disease: Erythropoiesis-stimulating agents (ESA) and iron supplements are typically used to treat anemia in patients with CKD and result in an increase of the hemoglobin (Hb) concentration to the goal of 10–11 g/dL in the USA and 10–12 g/dL in other parts of the world.